Thursday, October 5, 2017

Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost

Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost
By Josh Bloom — October 5, 2017

I have also written about the benefit of second- and third-generation drugs, which are dismissed as "me-too" drugs by know-nothing critics of the industry, such as Sidney Wolfe and Marcia Angell. Ignorant critics would have you believe that the fourth approved drug in a class is nothing more than a non-innovative cash cow for drug companies. They could hardly be more wrong.

It is now clear that patients benefit greatly when there are multiple choices of drugs for a particular ailment; not just medically, but also economically. There can be no better example of this than AbbVie's Mavyret, the newest weapon in the already-impressive arsenal against hepatitis C—a pernicious virus that has infected 3 million people in the US and 170 million worldwide.

Read More

No comments:

Post a Comment